Delving into the Latest Updates on Beijing Likang Life Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

TCR therapy

Therapeutic vaccine

T-lymphocyte cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	4

Top 5 Drug Type	Count

TCR therapy	2
Therapeutic vaccine	1
Personalized antigen vaccine	1
mRNA vaccine	1
T-lymphocyte cell therapy	1

主要目的评价LK101注射液单药治疗在晚期实体瘤患者中的安全性和耐受性。次要目的评价LK101注射液单药在不同免疫程序下的特异性T细胞免疫反应；？初步评价LK101注射液单药治疗的疗效。探索性目的探索与LK101注射液疗效和安全性相关的免疫学指标；探索肿瘤免疫微环境变化与LK101注射液疗效的相关性。

[Translation]

Primary objective To evaluate the safety and tolerability of LK101 injection monotherapy in patients with advanced solid tumors. Secondary objective To evaluate the specific T cell immune response of LK101 injection monotherapy under different immune programs; ? To preliminarily evaluate the efficacy of LK101 injection monotherapy. Exploratory objective To explore the immunological indicators related to the efficacy and safety of LK101 injection; To explore the correlation between changes in the tumor immune microenvironment and the efficacy of LK101 injection.

Start Date-

Sponsor / Collaborator

Beijing Likang Life Technology Co., Ltd.

NCT06054932

/ RecruitingPhase 1

A Phase I Study of LK101 Monotherapy in Participants With Advanced Solid Tumors to Evaluate the Safety, Tolerability, and Immunogenicity

This is an open-labeled, single-center phase I study in patients with incurable advanced solid tumors, who failed with all previous standard therapy. The aim is to observe and evaluate the safety, tolerability, and immunogenicity of LK101 injection.

Start Date05 Sep 2023

Sponsor / Collaborator

Beijing Likang Life Technology Co., Ltd.

NCT03674073

/ Unknown statusPhase 1IIT

A Study to Assess the Safety, Feasibility, and Immunogenicity of Personalized Neoantigen-based Dendritic Cell Vaccine in Combination With Microwave Ablation to Treat Hepatocellular Carcinoma

This is a single institution, open-label, multi-arm, pilot study of a personalized neoantigen-based dendritic cell (DC) vaccine combined with microwave ablation in subjects with Hepatocellular Carcinoma (HCC). Patients with HKLC stage IIa HCC are eligible for enrollment. In this study, the investigators are looking at the safety, feasibility of the personalized neoantigen-based DC vaccine combined with microwave ablation as well as the T cell immune response to the vaccine.

Start Date15 Oct 2018

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

[+1]

100 Clinical Results associated with Beijing Likang Life Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Likang Life Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Likang Life Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Likang Life Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LK101	Advanced Malignant Solid Neoplasm More	Phase 1
LK-Neo TCR-T (Likang Life Sciences)	Neoplasms More	Preclinical
LK-Neo ACT (Likang Life Sciences)	Neoplasms More	Preclinical
LK-Public TCR-T (Likang Life Sciences)	Neoplasms More	Preclinical